Thoratec HeartMate II Continuous-Flow LVAD Poses “Acceptable” Risks
This article was originally published in The Gray Sheet
Executive Summary
A new study of Thoratec's HeartMate II continuous-flow left-ventricular assist device supports the growing consensus that patient selection has a far greater influence than device selection on the mortality rate of LVAD patients